Enasidenib Mesylate clinical trials

Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation

This study looks at a new drug, enasidenib, for children and young people (aged 2-21) with a type of blood cancer called Acute Myeloid Leukemia (AML) that has come back or is hard to treat. It focuses on those with a specific genetic change in their cancer cells.